Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP
inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by …

Purpose: PARP inhibition (PARPi) has modest clinical activity in recurrent BRCA-mutant (BRCA
MUT ) high-grade serous ovarian cancers (HGSOC). We hypothesized that PARPi …

OBJECTIVES: To report long-term survival and toxicity of radiation compared with pelvic node
resection for patients with groin node–positive vulvar cancer. METHODS: A Gynecologic …

PARP inhibition is known to be an effective clinical strategy in BRCA mutant cancers, but PARP
inhibition has not been applied to BRCA-proficient tumors. Here, we show the synergy of …

Objective Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited
treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) …

BACKGROUND. Poly(ADP-ribose) polymerase (PARP) inhibitors are effective in a broad
population of patients with ovarian cancer; however, resistance caused by low enzyme …

Background Despite our substantial understanding of molecular mechanisms and gene
mutations involved in cancer, the technical approaches for diagnosis and prognosis of cancer …

Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to
platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance …

Purpose This study was performed to determine whether or not in cervical, ovarian and lung
cancer cell lines, free radicals (ROS) play a role in cisplatin cytotoxicity and activation of the …

CCNE1-amplified ovarian cancers (OVCAs) and endometrial cancers (EMCAs) are associated
with platinum resistance and poor survival, representing a clinically unmet need. We …